STAT5 as a Key Protein of Erythropoietin Signalization

Zuzana Tóthová 1, Jana Tomc 2, Nataša Debeljak 2(*) and Peter Solár 1, *(*)

1 Institute of Medical Biology, Faculty of Medicine, P. J. Šafárik University in Košice, 04011 Košice, Slovakia; zuzana.tothova1@student.upjs.sk
2 Medical Centre for Molecular Biology, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia; jana.tomc@mf.uni-lj.si (J.T.); natasa.debeljak@mf.uni-lj.si (N.D.)

* Correspondence: peter.solar@upjs.sk; Tel.: +421-55-234-3278; Fax: +421-55-6222124

Abstract: Erythropoietin (EPO) acts on multiple tissues through its receptor EPOR, a member of a cytokine class I receptor superfamily with pleiotropic effects. The interaction of EPO and EPOR triggers the activation of several signaling pathways that induce erythropoiesis, including JAK2/STAT5, PI3K/AKT, and MAPK. The canonical EPOR/JAK2/STAT5 pathway is a known regulator of differentiation, proliferation, and cell survival of erythroid progenitors. In addition, its role in the protection of other cells, including cancer cells, is under intense investigation. The involvement of EPOR/JAK2/STAT5 in other processes such as mRNA splicing, cytoskeleton reorganization, and cell metabolism has been recently described. The transcriptomics, proteomics, and epigenetic studies reviewed in this article provide a detailed understanding of EPO signalization. Advances in this area of research may be useful for improving the efficacy of EPO therapy in hematologic disorders, as well as in cancer treatment.

Keywords: STAT5; erythropoietin; erythropoietin receptor

1. STAT5 Signaling and Erythropoiesis

In classical erythropoiesis, erythropoietin (EPO) binds to an EPO receptor (EPOR) homo-dimer, activating EPO/EPOR signal transduction. EPO has two non-identical binding sites on EPORs: a high-affinity G151 (nano-molar) on the first and a low-affinity R103 (micro-molar) on the second receptor. The main signal cascades activated by EPO are JAK2/STAT5, PI3K/AKT, and MAPK. The canonical EPOR/JAK2/STAT5 pathway is a known regulator of differentiation, proliferation, and cell survival of erythroid progenitors. In addition, its role in the protection of other cells, including cancer cells, is under intense investigation. The involvement of EPOR/JAK2/STAT5 in other processes such as mRNA splicing, cytoskeleton reorganization, and cell metabolism has been recently described. The transcriptomics, proteomics, and epigenetic studies reviewed in this article provide a detailed understanding of EPO signalization. Advances in this area of research may be useful for improving the efficacy of EPO therapy in hematologic disorders, as well as in cancer treatment.
fragment of STAT5 with its N- and C-terminus [8]. Established STAT5 dimers are recognized by importins—importin α3 and β1, respectively—which allow them to translocate into the nucleus [8]. STAT5 binds as a dimer or tetramer to palindromic gamma-activated sequences called GAS0 motifs (TTCYXRGAA) in promoters and enhancers of target genes, resulting in their transcription [10]. The proto-oncogene tyrosine-protein kinase Src (SRC) can directly phosphorylate tyrosine residue 694 (pY694) of STAT5 and so contribute to EPO-induced signal transduction via STAT5 [11]. FYN, an Src-family tyrosine kinase, also participates in the EPO signaling pathway, since Fyn−/− mice exhibit reduced tyrosine phosphorylation of EPOR and decreased STAT5 activity. The importance of FYN in erythropoiesis is also supported by the blunted responsiveness of Fyn−/− mice to stress erythropoiesis [12]. Another member of the Src-family tyrosine kinases, LYN, is involved in tyrosine phosphorylation and activation of STAT5, mainly on tyrosine residue 694 (pY694) [13]. Besides, CRK-like adapter protein (CRKL) seemed to have a role in STAT5 activation since direct binding of CRKL to STAT5 was observed after EPO stimulation in an (EPO)-dependent cell line UT-7/EPO [14].

Recently, 121 new signals and/or EPO/EPOR/JAK2 target proteins, together with their EPO-modulated domains and phosphosites (e.g., pT349, pS358 and others), were identified. These included actin assemblage modifiers with adaptors DLG-1, DLG-3, WAS, WASL, and CD2AP, and erythroid cytoskeletal targets such as spectrin A, spectrin B, adducin 2, and glycophorin C. Metabolic regulators such as aldolase A, pyruvate dehydrogenase α1, and thioredoxin-interacting protein were also found as an EPO target set [15]. Furthermore, the same authors identified several novel EPO-modified kinases and phosphatases, including membrane palmitoylated protein 1, guanylate kinase 1, pseudopodium enriched atypical kinase 1, AP2 associated kinase 1, protein tyrosine phosphatase receptor type A, phosphohistidine phosphatase 1, tensin 2, ubiquitin-associated and SH3 domain-containing B (UBASH3B), and protein tyrosine phosphatase non-receptor type 18 (PTPN18). Due to its high expression in hematopoietic progenitors, PTPN18 has been further investigated, and it was revealed that PTPN18 promotes ERK1/2, AKT, STAT5, and JAK2 signals for EPO-dependent hematopoietic cell growth (Figure 1, Table 1) [15].

### Table 1. Main players of JAK2/STAT5 signaling cascade.

| Gene   | Gene ID | Protein Name                                           | Mechanism                          | Reference |
|--------|---------|--------------------------------------------------------|------------------------------------|-----------|
| JAK2   | 3717    | Tyrosine-protein kinase JAK2                           | EPORactivation                     | [16]      |
| STAT5A | 20850   | Signal transducer and activator of transcription 5A    | Signal transduction and activation of transcription of genes of erythroid differentiation | [5]       |
| STAT5B | 6777    | Signal transducer and activator of transcription 5B    |                                     |           |
| LYN    | 4067    | Tyrosine-protein kinase Lyn                            | Phosphorylation/activation of STAT5 | [13]      |
| SRC    | 6714    | Proto-oncogene tyrosine-protein kinase Src             | Phosphorylation/activation of CRKL  | [13]      |
| FYN    | 2534    | Tyrosine-protein kinase Fyn                            | Phosphorylation/activation of STAT5 | [17]      |
| CRKL   | 1399    | CRK-Like protein                                       | Phosphorylation/activation of STAT5 | [14,18]   |
| PTPN18 | 26469   | Tyrosine-protein phosphatase non-receptor type 18      | Activation of STAT5                | [15]      |
| KPN4   | 3840    | Importin subunit alpha-3                               | Nuclear import/export              | [9,19]    |
| KPNB1  | 3837    | Importin subunit beta-1                                |                                     |           |
| XPO1   | 7514    | Exportin-1 (CRM1)                                      |                                     |           |
| GATA1  | 2623    | Erythroid transcription factor                         | Regulation of STAT5 target gene transcription | [20]      |
### Table 1. Cont.

| Gene   | Gene ID | Protein Name                        | Mechanism                                           | Reference |
|--------|---------|-------------------------------------|-----------------------------------------------------|-----------|
| KLF1   | 10661   | Krueppel-like factor 1              | Regulation of STAT5 target gene transcription       | [20]      |
|        |         |                                     | Transcription factor                                 |           |
| TAL1 (SCL) | 6886  | T-cell acute lymphocytic leukemia protein1 | Regulation of STAT5 target gene transcription       | [21]      |
|        |         |                                     | Transcription factor                                 |           |
|        |         |                                     | STAT5 target gene                                   |           |
| BCL2L1 | 598     | Bcl-2-like protein 1 (apoptosis regulator Bcl-X) | STAT5 target gene                                   | [20]      |
| CLINT1 | 9685    | Clathrin interactor 1 (EPSINR)      | EPOR internalization & negative feedback for EPO-induced signaling | [20]      |
| CISH   | 1154    | Cytokine-inducible SH2-containing protein | STAT5 target gene                                   | [20,22,23]|
|        |         |                                     | Inhibition of STAT5 signaling                        |           |
|        |         |                                     | Degradation of EPOR                                  |           |
| SOCS1  | 8651    | Suppressor of cytokine signaling 1  | STAT5 target gene                                   | [22]      |
|        |         |                                     | JAK2 degradation                                     |           |
|        |         |                                     | Inhibitor of EPO signaling/Inhibition of STAT5 signaling |           |
| SOCS2  | 8835    | Suppressor of cytokine signaling 2  | STAT5 target gene                                   | [22]      |
|        |         |                                     | Inhibition of STAT5 signaling                        |           |

**Figure 1.** EPOR-STAT5 signaling and its involvement in processes other than inhibition of apoptosis, cell cycle progression, and cell cycle arrest. Green line: activation effect (phosphorylation); red line: inhibition effect; black line: transition.
2. The Interplay of EPO Signaling, Transcription Patterns, and Epigenetics

EPO-dependent STAT5 target genes involved in erythropoiesis are well-known. These are the following: Bcl-XL, Bcl2l1, Pim1, Cish, Socs3, Podocalyxin, Maltr3, Chac1, Ccrn4l, Socs2, Tnfr-sf13c, Lrp8, Cmtm6, Gdf3, Oncostatin-m, Rpl12, Ly11, Gas5, Pim3, Bim, Trb3, Serpina-3G, Irs2, Suv420h2, Gypc, Cdc25a, Btg3, p27-kip1, Trb2, Klf3, Cyclin-G2, Cyclin-D2, CyclinB1-IP-1, Spi2A, and others [20,24,25]. Some of these STAT5 target genes are negative regulators of STAT5 signaling. For example, proto-oncogene serine/threonine-protein kinase Pim-1 (PIM1) suppresses cytokine signaling 1 (SOCS1) and SOCS3. PIM1, however, does not bind directly to STAT5. It interacts with SOCS1 and SOCS3 and potentiates their inhibitory effects on STAT5, most likely via phosphorylation-mediated stabilization of the SOCS proteins [24]. STAT5 activity is also regulated via the inhibitory mechanism of tyrosine-protein phosphatase non-receptor type 6 (SHP-1, encoded by PTPN6 gene) which associates with the tyrosine-phosphorylated cytoplasmic domain of the EPOR. Moreover, SH2B adapter protein 3 (Lnk—signal transduction protein) involved in the signaling of cytokine receptors inhibits erythropoiesis and EPO-dependent JAK2 activation together via downstream signaling pathways [26]. The authors demonstrated that Lnk blocks STAT5 pathways induced by EPO in primary erythroblasts. In addition, SH2B adapter protein 2 suppresses EPO-induced STAT5 activation through the binding and a masking effect on STAT5 docking sites of EPOR. Negative feedback on EPO-induced signaling also provides CISH protein (the CISH gene is a direct target of STAT5), which binds activated pY401 of EPOR. Similar to other SOCS family members, CISH forms a complex with elongin B, elongin C, cullin5, and Rbx2. Such complex functions as an E3 ubiquitin ligase for ubiquitination and subsequent proteasomal degradation of EPOR [20]. SOCS3, however, provides a slightly different feedback dynamic compared to that of CISH. It also contains an N-terminal KIR peptide that directly affects STAT5 binding via JAK2. Gillinder et al. [20] suggested another STAT5-dependent negative feedback loop of EPOR downregulation. They reported that Clint1 (EpsinR) might enhance the internalization and/or endocytosis of EPOR through the association with clathrin-coated vesicles (Figure 1, Table 1). Other than Socs1 and Socs3, Socs2, Spred1, Spred2, and Eaf1 were also found as EPO/EPOR target genes and negative-feedback components of EPO-induced erythropoiesis during anemia [25].

Many new targets have emerged in EPOR/JAK2/STAT5 signaling in erythroid cells. Singh et al. [25] found 160 EPO/EPOR target transcripts that were significantly modulated (2—21.8-fold) in primary bone marrow-derived CFU-e-like progenitors. In another study, over 300 genomic locations, predominantly in promoter distal enhancer regions, were occupied by STAT5 within 30 min of EPO stimulation in murine J2E cells. Several newly discovered EPO-responsive target genes were involved in driving erythroid cell differentiation, including those involved in mRNA splicing (Rbm25), epigenetic regulation (Suv420h2), and EPO turnover (Clint1/EpsinR) [20]. Interestingly, STAT5-binding locations linked to erythroid-related genes were co-occupied by GATA1, KLF1, and/or TAL1 transcription factor [20]. However, housekeeping genes were bound by STAT5 without GATA1 and KLF1 [21]. While STAT5 was not enriched at the promoters of the master regulator genes in J2E cells, it was enriched at the GATA1 and TAL1 promoters of human erythroleukemic K562 cells [27].

The occupation of STAT-binding sites seems to be cell-type- and developmental-stage-specific. That makes the signaling pathways, epigenetic, and transcriptional changes downstream of EPOR unique in different kinds of cells. For example, in the well-designed study, novel factors such as REST, an epigenetic modifier central to neural differentiation and plasticity, and NFR1, a key regulator of antioxidant response and mitochondrial biogenesis, were found in fetal neural progenitor cells. EPO treatment of these cells also altered the epigenetic landscape, identifying 1150 differentially bound histone H3 lysine 4 dimethylated regions, which are known as active and poised enhancers and transcription start sites [28]. The most recent studies revealed that the EPOR signaling axis is comprised of an exceedingly complex system of molecular signaling, epigenetic modifications, and...
transcriptional dynamics. The data of Schulz et al. [29] demonstrated that chromatin states vary by individual erythroid stages, with significant transition between some stages. This suggests that stage-specific transcription of genes is gradual and hierarchical process with many cis-regulatory elements included [30]. Recently, Perreault et al. [31] discovered that rapid EPO-induced transcription in murine model of erythropoiesis occurs within invariant pre-established chromatin structure. HiChIP analysis revealed chromatin contacts between H3K27ac (epigenetic modification to the DNA packaging protein Histone H3) and ubiquitous transcription factor Yin Yang 1 which was distributed to surrounding areas of EPO-regulated genes.

In fact, evidence is emerging that specific chromatin remodeling is required for STAT binding to a subset of loci, and epigenetic regulation is a crucial and dynamic part of their gene regulation activity. Multiple studies have shown that STAT5 can also function as a transcriptional repressor by recruiting demethylating or deacetylating epigenetic modifiers to specific gene loci [32]. An experiment with EPO starvation to monitor the gene expression profile of pro-erythroblasts derived from primary fetal liver cells was carried out. In this regard, EPO induced the expression of hundreds of genes involved in the cell signaling related to the survival and identity of cells [21]. Cell identity is established and propagated primarily through epigenetic mechanisms, including the cell type-specific repertoire of enhancers [33]. The function of EPO signaling and its impact on epigenome became a high point of interest. Recently, the locations of the landscape of erythroid-specific enhancers have been determined in murine and human cell systems [34]. However, the detailed epigenetic and transcriptional patterns by which EPO signaling controls erythroid gene expression remain incompletely understood. Although transcription factors frequently bind to promoters, their predominant genome-wide distributions reside within distal enhancer regions. Enhancers are distinguished from promoters by histone modifications. Promoters are marked by histone 3 lysine 4 trimethylation (H3K4me3), while enhancer elements are demarcated by histone 3 lysine 4 monomethylation (H3K4me1) and histone 3 lysine 27 acetylation (H3K27ac) [35].

To uncover how EPO modulates the erythroid epigenome, an epigenetic profiling study was performed using an ex vivo murine cell system that underwent synchronous erythroid maturation in response to EPO stimulation [36]. Authors revealed a cis-regulatory network of thousands of EPO-responsive enhancers, of which EPO stimulation altered the histone mark signatures, highlighting EPO’s important role in reprogramming the epigenome. However, to what extent are these results comparable to humans remains unclear. Moreover, it was found that many enhancers modulated by EPO stimulation were linked to genes involved in cell-signaling pathways, such as JAK/STAT (n = 24), PI3K (n = 45), and FOXO (n = 25). The epigenetic landscape near genes involved in regulating the actin cytoskeleton (n = 31), glycosylation (n = 153), and transport (n = 221) was also altered within the first hour of exposure, suggesting that cytoskeletal reorganization may be regulated in part at the epigenetic level.

3. EPO/EPOR/STAT5 Signaling in Cancer Cells

3.1. In Vitro Studies

Mutational analysis of the eight EPOR tyrosine residues indicated that three of them, Y343, Y460, and Y464, are required for the JAK2 V617F mutant to exhibit its oncogenic activity. Moreover, phosphorylation at these three residues was necessary for full activation of STAT5, which is a critical downstream mediator of JAK2 V617F-induced oncogenic signaling [37]. Jeong et al. [38] showed that both the prostate cancer cell lines, as well as the primary prostate tissue, express functional EPOR, which was demonstrated via the dose-dependent proliferative response to EPO and EPO-induced STAT5B phosphorylation in cells. The activation of STAT5 was also confirmed during EPO-directed suppression of apoptosis in erythroleukemic cell lines, so STAT5 was functionally implicated in the EPO-dependent survival of cells [39]. The antiapoptotic effects of EPO in both neuronal differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells require “classi-
cal homodimeric EPOR and the combinatorial activation of multiple signaling pathways, including STAT5, AKT, and potentially MAPK, which is comparable to that observed in hematopoietic cells (Table 2) [40].

Although EPO stimulation of cultured EPOR-expressing breast cancer cells did not result in increased proliferation, overactivation of EPOR (receptor phosphorylation) or a consistent activation of canonical EPOR signaling pathway mediators such as JAK2, STAT3, STAT5, or AKT were observed [41]. EPO-induced activation of the JAK2/STAT5, PI3K/AKT, and RAS/ERK pathways has been shown to promote malignant cell behavior in benign, non-invasive rat mammary cell lines stably transfected with human EPOR [42]. However, EPO stimulated the activation of the extracellular signal-regulated kinase p38 and c-Jun-NH(2)-kinase in MCF-7 cells but did not activate AKT or STAT5 [43]. Similarly, EPO had no effect on the JAK2/STAT5 signal transduction in MDA-MB-231 or in MDA-MB-435 cells [44].

Non-small cell lung carcinoma (NSCLC) cell line H838 expresses functional EPORs and their treatment with EPO-reduced cisplatin-induced apoptosis [45]. Another three NSCLC cell lines, A427, A549, and NCI-H358, were analyzed for the expression of EPO and its downstream signaling pathways JAK2, STAT5, PI3K, and ERK. All cell lines expressed both mRNA and proteins of EPOR, which were found constitutively phosphorylated with downstream STAT5, AKT, and ERK1/2 independently activated of EPO treatment [46]. Additionally, pharmacological concentrations of EPO activated JAK2/STAT5, RAS/ERK, and PI3K/AKT pathways in NSCLC cells without growth advantage for these cells [47]. On the contrary, EPO mediated the invasion of head and neck squamous cell carcinoma cells through the JAK2/STAT signaling pathway (Table 2) [48].

Similarly, the co-existence of JAK2 and phosphorylated-JAK2, and STAT5 and phosphorylated STAT5, which are all involved in the mitogenic signaling of EPO, has been found frequently in the cells of malignant tumors of female reproductive organs, stomach, choriocarcinoma, melanoma, and capillary endothelial cells. Most of the phosphorylated JAK2 or phosphorylated STAT5-positive cells, however, had disappeared after the injection of monoclonal antibodies against EPO or a soluble form of EPOR [49]. In HUVEC cells, the conditioned media of hypoxic and EPO-treated A2780 cells induced significant phosphorylation of STAT5 [50].

Table 2. The list of cell lines and tumors with impact of EPOR/STAT5 signaling on the cell processes.

| Cell Line/Tumor Type                                      | Effect of EPOR/STAT5                 | References |
|-----------------------------------------------------------|--------------------------------------|------------|
| Myeloproliferative neoplasms, secondary acute myeloid leukemia | Cell survival, proliferation and migration | [51]       |
| Prostate cancer cell lines, primary prostate tissue        | Proliferation                        | [38]       |
| Erythroleukemic cell lines                                | Cell survival                        | [39]       |
| Neuronal differentiated neuroblastoma SH-SY5Y, Pheochromocytoma PC-12 | Cell survival                        | [40]       |
| Breast cancer cells                                       | Cell survival                        | [41]       |
| Non-small-cell lung carcinoma (NSCLC) cell line H838      | Cell survival                        | [45]       |
| NSCLC cell lines A427, A549, and NCI-H358 cell lines      | No effect                            | [46]       |
| Head and neck squamous cell carcinoma cells               | Tumor invasion                       | [48]       |
| Multiple myeloma endothelial cells (MMEC)                 | Angiogenesis                         | [52]       |
| Benign non-invasive rat mammary cell lines stably transfected with human EPOR | Malignant cell behavior              | [42]       |

3.2. In Vivo Studies and Patients

To date, epoetin alpha, beta, and darbepoetin alpha have been approved for anemia treatment in cancer patients. Although epoetins act on the same EPOR, differences in pharmacodynamics and pharmacokinetics through variations in glycolylation degree are expected. However, though both epoetins alpha and beta demonstrated comparable
efficacy and safety profiles, epoetin beta achieved targeted hematocrit levels with lower doses [53] and kept the occurrence of hemoglobin levels above 13 g/dL in EPO-treated end-stage renal disease hemodialysis patients [54].

Under physiological conditions, STAT5 expression is regulated by prolactin, growth hormone, insulin growth factor, estrogen, and progesterone signaling pathways, and plays a significant role in a normal mammary cell differentiation, proliferation, and survival [55]. Watowich et al. [56] have shown a lack of specificity of STAT signaling during red blood cell development. However, the importance of STAT5A/B proteins in the erythroid differentiation activated by EPO/EPOR/JAK2 signaling has been well demonstrated [20,21]. Although deletion of erythroid STAT5A/B resulted in anemia [57], Villarino et al. [58] found no difference in the hematocrit of single-allele expressing mice. STAT5A/B are up-regulated in myeloproliferative neoplasms, acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and B-cell and peripheral T-cell leukemia/lymphoma [51].

Increased STAT5A/B activation is achieved by gains in copy number, by upregulation of protein expression, or gain-of-function (GOF) mutations, which can lead to a higher phosphorylated form of STAT5A/B levels (pYSTAT5A/B) followed by tumor cell survival and disease progression [5]. The research in mature NK-T-cell neoplasms is currently focused on the recurrent point mutations localized mainly in the SH2 domain of STAT5B. The most frequent mutation, STAT5B$^{N642H}$, was observed in many forms of peripheral T-cell leukemia/lymphomas [59–61] and has also been detected in myeloid neoplasia with eosinophilia [62] and neutrophilic leukemia [63]. Moreover, a transgenic mouse model with STAT5B$^{N642H}$, under the hematopoietic vav-promoter, developed an aggressive CD8+ T-cell leukemia with organ infiltrations by CD8+, CD4+, and γδ T-cells [64,65]. The oncogenic role for STAT5B$^{N642H}$ was confirmed by a transplantation model derived from the transgenic mouse in NKT [66] and γδ T-cells [65] mentioned above.

Bone marrow-derived endothelial cells from monoclonal gammopathy (MGEC) of undetermined significance and multiple myeloma endothelial cells (MMEC) were assessed for the possibility that EPO might play a role in MGECs- and MMECs-mediated angiogenesis. Lamanuzzi et al. [52] showed that EPOR is expressed in both MGECs and MMECs, and at higher levels in the former (Table 2). Both EC types respond to recombinant human EPO (rHuEPO) in terms of cell proliferation and activation of JAK2/STAT5 and PI3K/AKT pathways. On the other hand, bone marrow-derived dendritic cells, which are direct targets of EPO, have demonstrated STAT3 rather than STAT5 activation [67]. Interestingly, the overexpression of HIF-1α, with stimulated EPO expression, diminished ROS levels and weakened cell damage caused by the iron overload in myelodysplastic syndrome patients [68]. Similarly, iron chelation therapy reduced the expression of SOCS1, recovered EPOR/STAT5 signalization, and reduced the apoptosis of immature erythrocytes in the bone marrow of low-risk myelodysplastic syndrome patients [69].

Similar signal transduction, including the STAT5 pathway, is mediated via EPOR-βcR, although EPOR splice variants [70] and EPOR-βcR heterodimers [71] have received much less consideration. The only difference in EPOR-βcR signaling compared with EPOR homodimer is the high concentration of EPO required. Ephrin-type B-receptor 4 (EPHB4) was also identified as an alternative EPOR that triggers downstream signaling via STAT3 and promotes recombinant human EPO-induced tumor growth and progression [72].

**4. EPO/EPOR/STAT5 Induced Protection of Normal Cells**

Protection mediated by EPO/EPOR/JAK2 results in pancreatic β cell proliferation and survival, increased angiogenesis, and reduced inflammation in the islets [73], as well as impaired pathogen clearance due to reduced production of anti-microbial TNF-α and NO molecules [74]. Recently, Li et al. [75] demonstrated that kidney-secreted cytokine EPO controls blood lipids in kidney disease. EPO has been shown to prevent necrotic ischemic injury and cisplatin-induced nephrotoxicity in primary mouse renal tubular epithelial cells [76] and human renal proximal tubular epithelial cells [77], possibly via JAK2/Y343/STAT5 signaling and Pim3 as a target gene of STAT5 [76]. EPO induced
The upregulation of STAT5 and its downstream gene products, Bcl-xL and XIAP, demonstrated significant protective effects on astrocytes (during 24–48 h anoxia) and A9 dopaminergic neurons of the substantia nigra [90]. Both effects were attenuated by inhibition of JAK2/STAT5 signaling [91]. In cultured cerebrocortical neurons, EPO/EPOR-triggered phosphorylation of STAT5 has been shown to activate nuclear factor κB (NF-κB) and subsequently induce expression of the antiapoptotic proteins X-linked inhibitor of apoptosis (XIAP) and c-inhibitor of apoptosis-2 (cIAP2), which in turn suppress caspase 3, 8, and 9 [92]. Interestingly, EPO-mediated neuroprotection involves cross-talk between JAK2 and NF-κB signal cascades [93]. Although not required for neuroprotection of EPO in hippocampal neurons, STAT5 is essential for EPO-neurotrophic activity [94]. In the detached retina, EPO activates both PI3K/AKT and MAPK/ERK-1/2 signal transduction pathways. Intravitreal injection of EPO has been demonstrated to protect both retinal vascular and neuronal cells in early diabetes via the activation of ERK but not the STAT5 pathway [95]. Conversely, EPO reduces insulin resistance and increases glucose uptake in adipocytes through the activation of AKT and STAT5 [96].

In rats with experimental epilepsy, EPO protected myocardial cells from apoptosis via the JAK2/STAT5 pathway, and the inhibition of JAK2/STAT5 signalization by AG490 reduced the antiapoptotic effects of EPO [97]. On the other hand, carbamyl-EPO variants and pharmacological doses of EPO (250 IU/mL) exerted antiapoptotic activity in myocardial cells [98] and vascular smooth muscle cells (VSMCs) [99], respectively, via a pathway independent of JAK2/STAT5 signaling. In addition, modulating activities of EPO on adaptive and innate cells of immune systems are reviewed in Cantarelli et al. [100].
5. Conclusions

Recently, several new target genes of the EPO/EPOR/STAT5 signaling cascade have been discovered, especially in erythroid cells. These genes and their protein products are mainly involved in the processes of epigenetic regulation, mRNA splicing, molecular signaling, EPOR turnover, and negative regulation of STAT5 signaling. However, they can also be implicated in the regulation of cell metabolism and cytoskeletal reorganization. Transcriptomic analyses and mapping of EPO/EPOR target genes are also necessary for tumor and normal cells, on which only signaling and the effect of EPO/EPOR have been described so far, e.g., protective, antiapoptotic, trophic, and other. New EPO/EPOR target genes in cancer cells could serve as markers for various means of monitoring both disease activity and cell responses to various therapies, including the administration of rHuEPO to tumor patients.

6. Source of Data

We reviewed most recent scientific papers and the data from the biomedical literature found in PubMed. Studies were obtained using the following keywords: “STAT5” or “erythropoietin” or “erythropoietin receptor” and “erythropoiesis” or “cancer cell” or “normal cell” or “signaling”.

Author Contributions: Z.T., J.T. and P.S. were responsible for the conception, collection of data and design of figure and tables. Manuscript was drafted by Z.T. and P.S. and critically revised by J.T. and N.D. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: This study was supported by the Scientific Grant Agency of the Ministry of Education of the Slovak Republic by grant No. VEGA1/0536/19.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Debeljak, N.; Sytkowski, A.J. Erythropoietin: New approaches to improved molecular designs and therapeutic alternatives. *Curr. Pharm. Des.* 2008, 14, 1302–1310. [CrossRef]
2. Kim, A.R.; Ulirsch, J.C.; Wilmes, S.; Unal, E.; Moraga, I.; Karakukcu, M.; Yuan, D.; Kazerounian, S.; Abdulhay, N.J.; King, D.S.; et al. Functional Selectivity in Cytokine Signaling Revealed Through a Pathogenic EPO Mutation. *Cell* 2017, 168, 1053–1064.e1015. [CrossRef] [PubMed]
3. Moraga, I.; Wernig, G.; Wilmes, S.; Gryshkova, V.; Richter, C.P.; Hong, W.J.; Sinha, R.; Guo, F.; Fabionar, H.; Wehrman, T.S.; et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. *Cell* 2015, 160, 1196–1208. [CrossRef] [PubMed]
4. McGraw, K.L.; Fuhler, G.M.; Johnson, J.O.; Clark, J.A.; Caceres, G.C.; Sokol, L.; List, A.F. Erythropoietin receptor signaling is membrane raft dependent. *PLoS ONE* 2012, 7, e34477. [CrossRef] [PubMed]
5. Maurer, B.; Kollmann, S.; Pickem, J.; Hoelbl-Kovacic, A.; Sexl, V. STAT5A and STAT5B-Twins with Different Personalities in Hematopoiesis and Leukemia. *Cancers* 2019, 11, 1726. [CrossRef] [PubMed]
6. Menon, M.P.; Karur, V.; Bogacheva, O.; Bogachev, O.; Cuetara, B.; Wojchowski, D.M. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. *J. Clin. Investig.* 2006, 116, 683–694. [CrossRef]
7. Yoon, D.; Watowich, S.S. Hematopoietic cell survival signals are elicited through non-tyrosine-containing sequences in the membrane-proximal region of the erythropoietin receptor (EPOR) by a Stat5-dependent pathway. *Exp. Hematol.* 2003, 31, 1310–1316. [CrossRef] [PubMed]
8. Cumaraswamy, A.A.; Lewis, A.M.; Geletu, M.; Todice, A.; Diaz, D.B.; Cheng, X.R.; Brown, C.E.; Laister, R.C.; Muench, D.; Kerman, K.; et al. Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein. *ACS Med. Chem. Lett.* 2014, 5, 1202–1206. [CrossRef]
9. Ernst, S.; Muller-Newen, G. Nucleocytoplasmic Shuttling of STATs. A Target for Intervention? *Cancers* 2019, 11, 1815. [CrossRef]
10. Sathyarayana, B.K.; Li, P.; Lin, J.X.; Leonard, W.J.; Lee, B. Molecular Models of STAT5A Tetramers Complexed to DNA Predict Relative Genome-Wide Frequencies of the Spacing between the Two Dimer Binding Motifs of the Tetramer Binding Sites. *PLoS ONE* 2016, 11, e0160339. [CrossRef]
11. Okutani, Y.; Kitana, A.; Tanaka, T.; Kamano, H.; Ohnishi, H.; Kubota, Y.; Ishida, T.; Takahara, J. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. *Oncogene* 2001, 20, 6643–6650. [CrossRef]
12. Beneduce, E.; Matte, A.; De Falco, L.; Mbiandjeu, S.; Chiabrando, D.; Tolosano, E.; Federti, E.; Petrillo, S.; Mohandas, N.; Siciliano, A.; et al. Fyn kinase is a novel modulator of erythropoietin signaling and stress erythropoiesis. *Am. J. Hematol.* **2019**, *94*, 10–20. [CrossRef] [PubMed]

13. Chin, H.; Arai, A.; Wakao, H.; Kamiyama, R.; Miyasaka, N.; Miura, O. Lyn physically associates with the erythropoietin receptor and may play a role in the Stat5 pathway. *Blood* **1998**, *91*, 3734–3745. [CrossRef] [PubMed]

14. Ota, J.; Kimura, F.; Sato, K.; Wakimoto, N.; Nakamura, Y.; Nagata, N.; Suzu, S.; Yamada, M.; Shimamura, S.; Motoyoshi, K. Association of Crkl with Stat5 in hematopoietic cells stimulated by granulocyte-macrophage colony-stimulating factor or erythropoietin. *Biochem. Biophys. Res. Commun.* **1998**, *252*, 779–786. [CrossRef]

15. Held, M.A.; Greenfest-Allen, E.; Jachimowicz, E.; Stoeckert, C.J.; Stokes, M.P.; Wood, A.W.; Wojchowski, D.M. Phospho-proteomic discovery of novel signal transducers including thioredoxin-interacting protein as mediators of erythropoietin-dependent human erythropoiesis. *Exp. Hematol.* **2020**, *84*, 29–44. [CrossRef]

16. Ghoreschi, K.; Laurence, A.; O’Shea, J.J. Janus kinases in immune cell signaling. *Immunol. Rev.* **2009**, *228*, 273–287. [CrossRef]

17. Able, A.A.; Burrell, J.A.; Stephens, J.M. STAT5-Interacting Proteins: A Synopsis of Proteins that Regulate STAT5 Activity. *Biology* **2017**, *6*, 20. [CrossRef] [PubMed]

18. Arai, A.; Kanda, E.; Nosaka, Y.; Miyasaka, N.; Miura, O. CrkL is recruited through its SH2 domain to the erythropoietin receptor and plays a role in Lyn-mediated receptor signaling. *J. Biol. Chem.* **2001**, *276*, 33282–33290. [CrossRef] [PubMed]

19. Reich, N.C. STABs get their move on. *Nat. Rev. Genet.* **2002**, *3*, 189–195. [CrossRef] [PubMed]

20. Tong, W.; Zhang, J.; Lodish, H.F. Lnk inhibits erythropoiesis and Epo-dependent Jak2 activation and downstream signaling pathways. *Blood* **2005**, *105*, 4604–4612. [CrossRef]

21. Wang, J.; Friedman, G.; Doyon, Y.; Wang, N.S.; Li, C.J.; Miller, J.C.; Hua, K.L.; Yan, J.J.; Babiarz, J.E.; Gregory, P.D.; et al. Targeted deletion of genes in development: Concepts, mechanisms and consequences. *Exp. Hematol.* **2017**, *49*, 1–8. [CrossRef] [PubMed]

22. Perreault, A.A.; Venters, B.J. Erythropoietin Regulates Transcription and YY1 Dynamics in a Pre-established Transcription Network in Fetal Neural Progenitor Cells. *Cell Rep.* **2017**, *21*, e0180922. [CrossRef] [PubMed]

23. Bachmann, J.; Raue, A.; Schilling, M.; Bohm, M.E.; Kreutz, C.; Kaschek, D.; Busch, H.; Gretz, N.; Lehmann, W.D.; Timmer, J.; et al. Division of labor by dual feedback regulators controls Jak2/Stat5 signaling over broad ligand range. *Mol. Syst. Biol.* **2011**, *7*, 516. [CrossRef] [PubMed]

24. Peltola, K.J.; Paukku, K.; Aho, T.L.; Ruuska, M.; Silvennoinen, O.; Koskinen, P. Pim-1 kinase inhibits Stat5-dependent transcription via its interactions with SOCS1 and SOCS3. *Blood* **2004**, *103*, 3744–3750. [CrossRef]

25. Singh, S.; Dev, A.; Verma, R.; Pradeep, A.; Sathyanarayana, P.; Green, J.M.; Narayanan, A.; Wojchowski, D.M. Defining an EPOR-dependent erythropoietin regulatory landscape defines human erythropoiesis. *PLoS ONE* **2012**, *7*, e38530. [CrossRef]

26. Tong, W.; Zhang, J.; Lodish, H.F. Lnk inhibits erythropoiesis and Epo-dependent Jak2 activation and downstream signaling pathways. *Blood* **2005**, *105*, 4604–4612. [CrossRef]

27. Yang, X.P.; Ghoreschi, K.; Laurence, A.; O’Shea, J.J. Janus kinases in immune cell signaling. *Immunol. Rev.* **2002**, *3*, 189–195. [CrossRef] [PubMed]

28. Schulz, V.P.; Yan, H.; Lezon-Geyda, K.; An, X.; Hale, J.; Hillyer, C.D.; Mohandas, N.; Gallagher, P.G. A unique epigenomic landscape defines human erythropoiesis. *Cell Rep.* **2019**, *28*, 2996–3009.e2997. [CrossRef]

29. Bonifer, C.; Cockrell, P.N. Chromatin priming of genes in development: Concepts, mechanisms and consequences. *Exp. Hematol.* **2017**, *49*, 1–8. [CrossRef] [PubMed]

30. Shilyueva, D.; Stampfel, G.; Stark, A. Transcriptional enhancers: From properties to genome-wide predictions. *Nat. Rev. Genet.* **2014**, *15*, 272–286. [CrossRef]

31. Jeong, J.Y.; Hoxhaj, G.; Socha, A.L.; Sytkowski, A.J.; Feldman, L. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. *Mol. Cancer Res.* **2009**, *7*, 1150–1157. [CrossRef]

32. Bachmann, J.; Raue, A.; Schilling, M.; Bohm, M.E.; Kreutz, C.; Kaschek, D.; Busch, H.; Gretz, N.; Lehmann, W.D.; Timmer, J.; et al. Division of labor by dual feedback regulators controls Jak2/Stat5 signaling over broad ligand range. *Mol. Syst. Biol.* **2011**, *7*, 516. [CrossRef] [PubMed]

33. Calo, E.; Wysocka, J. Modification of enhancer chromatin: What, how, and why? *Mol. Cell* **2013**, *49*, 825–837. [CrossRef]

34. Buerger, K.; Benten, M.L.; Koury, M.J.; Brandt, S.J.; Venters, B.J. Epo reprograms the epigenome of erythroid cells. *Exp. Hematol.* **2017**, *51*, 47–62. [CrossRef] [PubMed]

35. Ueda, F.; Tago, K.; Yamada, M.; Funakoshi-Tago, M. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis. *J. Biol. Chem.* **2017**, *292*, 1826–1846. [CrossRef] [PubMed]

36. Jeong, J.Y.; Hoxhaj, G.; Socha, A.L.; Sytkowski, A.J.; Feldman, L. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. *Mol. Cancer Res.* **2009**, *7*, 1150–1157. [CrossRef]
61. Pham, H.T.T.; Hengstschlager, M.; Moriggl, R. A haunted beast: Targeting STAT5BN642H in T-Cell Neoplasia. Mol. Cell. Oncol. 2018, 5, e135181. [CrossRef]
62. Cross, N.C.P.; Hoade, Y.; Tapper, W.J.; Carreno-Tarragona, G.; Fanelli, T.; Jawhar, M.; Naumann, N.; Pieniak, I.; Lubke, J.; Ali, S.; et al. Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia 2018, 33, 415–425. [CrossRef]
63. Luo, Q.; Shen, J.; Yang, Y.; Tang, H.; Shi, M.; Liu, J.; Liu, Z.; Shi, X.; Yi, Y. CSF3R T618I, ASXL1 G942fs and STAT5B N642H truncation co-contribute to a rare chronic neutrophilic leukaemia manifested by rapidly progressive leukocytosis, severe infections, persistent fever and deep venous thrombosis. Br. J. Haematol. 2018, 180, 892–894. [CrossRef]
64. Pham, H.T.T.; Maurer, B.; Prchal-Murphy, M.; Grausenburger, R.; Grundsober, E.; Javaheri, T.; Nivarthi, H.; Boersma, A.; Kolbe, T.; Elabd, M.; et al. STAT5BN642H is a driver mutation for T-cell neoplasia. J. Clin. Invest. 2018, 128, 387–401. [CrossRef]
65. de Araujo, E.D.; Erdogan, F.; Neubauer, H.A.; Menekseoglu-Dolmaz, D.; Manasviyoungkul, P.; Eram, M.S.; Seo, H.K.; Qadree, A.K.; Israelian, J.; Orolova, A.; et al. Structural and functional consequences of the STAT5B(N642H) driver mutation. Nat. Commun. 2019, 10, 2517. [CrossRef]
66. Klein, K.; Vitalis-Siepracka, A.; Maurer, B.; Prinz, D.; Heller, G.; Leidenfrost, N.; Prchal-Murphy, M.; Suske, T.; Moriggl, R.; Sed, V. STAT5BN642H drives transformation of NKT cells: A novel mouse model for CD56(+) T-LGL leukemia. Leukemia 2019, 33, 2336–2340. [CrossRef] [PubMed]
67. Lifshitz, L.; Prutchi-Sagiv, S.; Avneon, M.; Gassmann, M.; Mittelman, M.; Neumann, D. Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells. Mol. Immunol. 2009, 46, 713–721. [CrossRef] [PubMed]
68. Zheng, Q.Q.; Zhao, Y.S.; Guo, J.; Zhao, S.D.; Song, L.X.; Fei, C.M.; Zhang, Z.; Li, X.; Chang, C.K. Iron overload promotes erythroid apoptosis through regulating HIF-1α/ROS signaling pathway in patients with myelodysplastic syndrome. Leuk Res. 2017, 58, 55–62. [CrossRef] [PubMed]
69. Zhang, Y. Effect of iron chelation therapy on EPO-STAT5 signalling pathway and EPO resistance in iron-overloaded low-risk myelodysplastic syndrome patients. Hematology 2020, 25, 10. [CrossRef] [PubMed]
70. Arcasoy, M.O.; Jiang, X.; Haroon, Z.A. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res. Commun. 2003, 307, 999–1007. [CrossRef]
71. Broxmeyer, H.E. Erythropoietin: Multiple targets, actions, and modifying influences for biological and clinical consideration. J. Exp. Med. 2013, 210, 205–208. [CrossRef] [PubMed]
72. Pradeep, S.; Huang, J.; Mora, E.M.; Nick, A.M.; Cho, M.S.; Wu, S.Y.; Noh, K.; Pecot, C.V.; Rupaimoole, R.; Stein, M.A.; et al. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell 2015, 28, 610–622. [CrossRef]
73. Choi, D.; Schroer, S.A.; Lu, S.Y.; Wang, L.; Wu, X.; Liu, Y.; Zhang, Y.; Gaisano, H.Y.; Wagner, K.U.; Wu, H.; et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J. Exp. Med. 2010, 207, 2831–2842. [CrossRef] [PubMed]
74. Nairz, M.; Sonneweber, T.; Schroll, A.; Theurl, I.; Weiss, G. The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect. 2011, 14, 238–246. [CrossRef]
75. Li, J.; Yang, M.; Yu, Z.; Tian, J.; Du, S.; Ding, H. Kidney-secreted erythropoietin lowers lipidemia via activating JAK2-STAT5 signaling in adipose tissue. BioMedicine 2019, 50, 317–328. [CrossRef] [PubMed]
76. Breggia, A.C.; Wojchowski, D.M.; Himmelfarb, J. JAK2/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells. Am. J. Physiol. Renal Physiol. 2008, 295, F1689–F1695. [CrossRef]
77. Salahudeen, A.K.; Haider, N.; Jenkins, J.; Joshi, M.; Patel, H.; Huang, H.; Yang, M.; Zhe, H. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Am. J. Physiol. Renal Physiol. 2009, 294, F1354–F1365. [CrossRef]
78. Chen, Z.; Zhan, Y.; Chi, J.; Guo, S.; Zhong, X.; He, A.; Zheng, J.; Gong, Y.; Li, X.; Zhou, L. Using microRNAs as Novel Predictors of Urologic Cancer Survival: An Integrated Analysis. EBioMedicine 2018, 34, 94–107. [CrossRef]
79. Alhasan, A.H.; Scott, A.W.; Wu, J.J.; Feng, G.; Meeks, J.J.; Thaxton, C.S.; Mirkin, C.A. Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. Proc. Natl. Acad. Sci. USA 2016, 113, 10655–10660. [CrossRef]
80. Felaco, P.; Felaco, M.; Franceschelli, S.; Ferrone, A.; Gatta, D.M.P.; Speranza, L.; Patruno, A.; De Lutiis, M.L.; Ballerini, P.; Siroli, V.; et al. Erythropoietin induces miRNA-210 by JAK2/STAT5 signaling in PBMCs of End-stage Renal Disease patients. FEBs J. 2020, 58, 5167–5182. [CrossRef]
81. Kaltenecker, D.; Mueller, K.M.; Beneditk, P.; Feiler, U.; Themanns, M.; Schlederer, M.; Kenner, L.; Schweiger, M.; Haemmerle, G.; Moriggl, R. Adipocyte STAT5 deficiency promotes adiposity and impairs lipid mobilisation in mice. Diabetologia 2017, 60, 296–305. [CrossRef] [PubMed]
82. Kaltenecker, D.; Spirk, K.; Ruge, F.; Grebien, F.; Herling, M.; Rupprech, A.; Kenner, L.; Pohl, E.E.; Mueller, K.M.; Moriggl, R. STAT5 is required for lipid breakdown and beta-adrenergic responsiveness of brown adipose tissue. Mol. Metab. 2020, 40, 101026. [CrossRef] [PubMed]
83. Tsuma, Y.; Mori, J.; Ota, T.; Kawabe, Y.; Morimoto, H.; Fukushima, S.; Kodo, K.; Unemura, A.; Nakajima, H.; Hosoi, H. Erythropoietin and long-acting erythropoiesis stimulating agent ameliorate non-alcoholic fatty liver disease by increasing lipolysis and decreasing lipogenesis via EPOR/STAT5 signaling. Biochem. Biophys. Res. Commun. 2019, 509, 306–313. [CrossRef] [PubMed]
84. Noguchi, C.T. Erythropoietin regulates metabolic response in mice via receptor expression in adipose tissue, brain, and bone. Exp. Hematol. 2020, 92, 32–42. [CrossRef]

85. Suresh, S.; Rajvanshi, P.K.; Noguchi, C.T. The Many Facets of Erythropoietin Physiologic and Metabolic Response. Front. Physiol. 2019, 10, 1534. [CrossRef]

86. Suresh, S.; Alvarez, J.C.; Dey, S.; Noguchi, C.T. Erythropoietin-Induced Changes in Bone and Bone Marrow in Mouse Models of Diet-Induced Obesity. Int. J. Mol. Sci. 2020, 21, 1657. [CrossRef] [PubMed]

87. Suresh, S.; Lee, J.; Noguchi, C.T. Effects of Erythropoietin in White Adipose Tissue and Bone Microenvironment. Front. Cell Dev. Biol. 2020, 8, 584696. [CrossRef]

88. Suresh, S.; Lee, J.; Noguchi, C.T. Erythropoietin signaling in osteoblasts is required for normal bone formation and for bone loss during erythropoietin-stimulated erythropoiesis. FASEB J. 2020, 34, 11685–11697. [CrossRef]

89. Marcuzzi, F.; Zucchelli, S.; Bertuzzi, M.; Santoro, C.; Tell, G.; Carninci, P.; Gustincich, S. Isoforms of the Erythropoietin receptor in dopaminergic neurons of the Substantia Nigra. J. Neurochem. 2016, 139, 596–609. [CrossRef] [PubMed]

90. Al-Sarraf, H.; Malatiali, S.; Al-Awadi, M.; Redzic, Z. Effects of erythropoietin on astrocytes and brain endothelial cells in primary culture during anoxia depend on simultaneous signaling by other cytokines and on duration of anoxia. Neurochem. Int. 2018, 113, 34–45. [CrossRef] [PubMed]

91. Digicaylioglu, M.; Lipton, S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001, 412, 641–647. [CrossRef]

92. Byts, N.; Samoylenko, A.; Fasshauer, T.; Ivanisevic, M.; Hennighausen, L.; Ehrenreich, H.; Siren, A.L. Essential role for Stat5 in the neurotrophic but not in the neuroprotective effect of erythropoietin. Cell Death Differ. 2008, 15, 783–792. [CrossRef] [PubMed]

93. Pan, Y.; Shu, J.L.; Gu, H.F.; Zhou, D.C.; Liu, X.L.; Qiao, Q.Y.; Fu, S.K.; Gao, F.H.; Jin, H.M. Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes. Mol. Cell. Endocrinol. 2013, 367, 116–123. [CrossRef] [PubMed]

94. Janmaat, M.L.; Heerkens, J.L.; de Bruin, A.M.; Klous, A.; de Vries, C.J. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. Blood 2010, 115, 1453–1460. [CrossRef]

95. Cantarelli, C.; Angeletti, A.; Cravedi, P. Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. Am. J. Transplant. 2019, 19, 2407–2414. [CrossRef]